Slowly Digestible Carbohydrates for GLP-1 Secretion
Purdue University · NCT07572513
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–45 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 19
- US sites recruiting
- 1
- Study start
- May 1, 2026
- Record last updated
- May 7, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The goal of this clinical trail is to learn if the hormone, glucagon-like peptide-1 (GLP-1), is stimulated by slowly digestible carbohydrates (SDCs) in healthy adults. In the current study, researchers will observe the amount of SDC that results in clinically meaningful levels of GLP-1, shown by an increase in feelings of fullness and a decrease in hunger, and how long an elevated level of GLP-1 lasts after starch consumption. Researchers aim to address two questions: What amount of SDC maximizes GLP-1-mediated satiety, and does the impact to satiety continue in a second meal? The overall goal is to maximize ileal-digesting SDC's potential use as a food-based agent for weight loss.
Researchers will compare 20, 40, and 60 g of raw corn starch compared to a maltodextrin control on total plasma GLP-1 concentrations, insulin, and blood glucose at baseline and 15, 30, 60, 90, 120, and 180 minutes post-consumption of SDC. Researchers will also measure satiety at baseline, 60, 120, 180 minutes and after a second meal.
There will be a total of 4 study visits with a least a 7-day break between visits. At each study visit, participants will:
- Consume a randomized test beverage (SDC or maltodextrin)
- Receive a blood draw at 7 timepoints over 3 hrs
- Take a satiety questionnaire 5 times over 3 hrs
- Consume a standardized lunch 3 hrs after the test beverage consumption
Being studied: Maltodextrin (Placebo); Raw Corn Starch
Conditions: Blood Glucose; GLP-1; Satiety; Second Meal Intake; Healthy Participant Study
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Healthy population
- BMI between 18.5 and 24.9 kg/m2
- Adults 18 - 45 years old
- Men or women
- Able to read/speak English
- Fasting blood glucose levels ≤100 mg/dL
- HbA1c ≤ 5.7%
Exclusion Criteria
- Participants with 18 > Years of Age > 45 will be excluded.
- Subjects with 18.5 kg/m² > BMI > 24.9 kg/m² will be excluded.
- Diabetic individuals will be excluded.
- Individuals with history of gastrointestinal disease will be excluded from the study.
- Pregnant or nursing women will also be excluded.
- Individuals taking GLP-1 medications, or on weight-loss diets or restrictive eating patterns.
- Individuals suffering from dairy or gluten intolerance or allergies will be excluded.
Recruiting US locations
Clinical Research Center at Purdue University
West Lafayette, IN 47907
Site contact: Cheryl Armstrong, Ph.D. · 765-496-6275 · armstroc@purdue.edu
Study contacts (from the official record)
- Bruce R Hamaker, Ph.D. · 765-494-5668 · hamakerb@purdue.edu
- Erica de Jong, B.s. · 7654963802 · dejonge@purdue.edu
Similar studies in Indiana
All nutrition & metabolism studies in Indiana →- RecruitingHealthy volunteers
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
Cleerly, Inc.
- Location
- Indianapolis, IN + 121 other US sites
- Eligibility basics
- Ages 55+
- RecruitingPhase 3
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Hoffmann-La Roche
- Location
- Hammond, IN + 121 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Hoffmann-La Roche
- Location
- Hammond, IN + 112 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 4
Safety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult Patients
Fresenius Kabi
- Location
- Indianapolis, IN + 3 other US sites
- Eligibility basics
- Ages 1 mo–17